In colorectal and pancreatic cancers, the TGF-β signalling pathway is frequently abolished by mutations in SMAD4 or TGFBR2 (Massagué, 2008; Levy and Hill, 2006). Here, TGFBR2 is linked to pancreatic neoplasm.